FTC Sues Prescription Drug Middlemen for Artificially Inflating Insulin Drug Prices – Includes Caremark, Express Scripts, Optum and Affiliates
FTC Sues Prescription Drug Middlemen for Artificially Inflating Insulin Drug Prices – Includes Caremark, Express Scripts, Optum and Affiliates
Federal Trade Commission accuses three drug middlemen of inflating insulin prices
In a lawsuit, the FTC accused Optum Rx, Caremark and Express Scripts of creating "a broken rebate system that inflated insulin drug prices, boosting PBM (prescription drug benefit managers) profits at the expense of vulnerable patients.
Federal Trade Commission sues largest drug middlemen for allegedly inflating insulin prices
The Federal Trade Commission took action Friday against the three largest pharmacy benefit managers, accusing the companies of artificially inflating insulin list prices that resulted in patients paying more for the medications.
FTC sues prescription drug middlemen, alleging they conspired over high insulin costs
The Federal Trade Commission on Friday filed lawsuits against three prescription drug benefit managers or PBMs over concerns the companies are artificially inflating the list price of insulin drugs.
FTC lawsuit claims drug middlemen are manipulating insulin market
Three companies that process about 80% of prescriptions in the United States — Caremark, Express Scripts and OptumRx — have engaged in anticompetitive practices that spur price increases, the
F.T.C. Accuses Drug Middlemen of Inflating Insulin Prices
The case takes aim at the major pharmacy benefit managers, agency officials said, claiming that they favored more expensive insulin products and forced patients to pay more.
FTC sues drug middlemen over manipulating the insulin market
The agency alleges CVS’s Caremark, Cigna’s Express Scripts and UnitedHealth’s Optum Rx accepted money from drugmakers in exchange for keeping lower-cost insulin off their lists of approved
FTC sues largest drug middlemen for allegedly inflating insulin prices
The Federal Trade Commission took action Friday against the three largest pharmacy benefit managers, accusing the companies of artificially inflating insulin list prices that resulted in patients payi
FTC goes after drug middlemen for allegedly jacking up insulin prices
The Big Three handle at least 80% of the country’s insulin prescriptions. The price of insulin has exponentially increased in recent years. Now, the Federal Trade Commission (FTC) is suing three companies over allegedly inflating the cost of the drug at the expense of Americans who rely on it.
US FTC sues drug 'gatekeepers' over high insulin prices
The U.S. Federal Trade Commission sued the country's three largest pharmacy benefit managers on Friday, accusing them of steering diabetes patients towards higher priced insulin in order to reap millions of dollars in rebates from pharmaceutical companies.
Drug middlemen illegally drive up the cost of insulin, FTC says
Regulators say the nation's largest pharmacy benefit managers are partly to blame for the soaring cost of insulin in the U.S.
While brand-name weight loss drugs are in short supply, a market for alternatives thrives
High demand for weight-loss and diabetes drugs like Ozempic and Wegovy has led to a shortage in manufacturing. In the ...
With TV Drug Ads, What You See Is Not Necessarily What You Get
The U.S. is one of only two countries that legally allows drugmakers to advertise products directly to patients. There are ...
Business Insider3d
Analysts Conflicted on These Healthcare Names: Teva Pharmaceutical (TEVA) and Adicet Bio (ACET)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Teva Pharmaceutical (TEVA – Research Report) and Adicet Bio (ACET – Research Report).
Qualifyze swallows $54M to improve pharmaceutical supply chains
In the world of pharmaceuticals, companies aim to operate under GMP guidelines — a set of production and manufacturing ...